Refine
Has Fulltext
- yes (7)
Is part of the Bibliography
- yes (7)
Document Type
Keywords
- Gesellschaften ohne Zentralgewalt (2)
- Konflikt (2)
- Soziologie des Dritten (2)
- CNS disease (1)
- MYC (1)
- Materielle Kultur (1)
- Negative Reziprozität (1)
- RNA polymerase II (1)
- SPT5 (1)
- SPT6 (1)
- SUPT5H (1)
- blood‐brain barrier (BBB) (1)
- bortezomib (1)
- directionality (1)
- drug permeability screening (1)
- elongation rate (1)
- first responders (1)
- human‐induced pluripotent stem cells (hiPSC) (1)
- induction regimen (1)
- kidney (1)
- lenalidomide (1)
- lessons learned (1)
- materielle Kultur (1)
- mission strategies (1)
- multiple myeloma (1)
- negative Reziprozität (1)
- oncology (1)
- preclinical drug discovery (1)
- processivity (1)
- renal failure (1)
- risk factors (1)
- safety (1)
- terror attack (1)
- transcription (1)
- tumorigenesis (1)
Institute
- Institut für Altertumswissenschaften (2)
- Theodor-Boveri-Institut für Biowissenschaften (2)
- Comprehensive Cancer Center Mainfranken (1)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (1)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (1)
- Lehrstuhl für Tissue Engineering und Regenerative Medizin (1)
- Medizinische Klinik und Poliklinik II (1)
- Rudolf-Virchow-Zentrum (1)
Fanconi anemia (FA) is a genetically heterogeneous disorder with 22 disease-causing genes reported to date. In some FA genes, monoallelic mutations have been found to be associated with breast cancer risk, while the risk associations of others remain unknown. The gene for FA type C, FANCC, has been proposed as a breast cancer susceptibility gene based on epidemiological and sequencing studies. We used the Oncoarray project to genotype two truncating FANCC variants (p.R185X and p.R548X) in 64,760 breast cancer cases and 49,793 controls of European descent. FANCC mutations were observed in 25 cases (14 with p.R185X, 11 with p.R548X) and 26 controls (18 with p.R185X, 8 with p.R548X). There was no evidence of an association with the risk of breast cancer, neither overall (odds ratio 0.77, 95%CI 0.44–1.33, p = 0.4) nor by histology, hormone receptor status, age or family history. We conclude that the breast cancer risk association of these two FANCC variants, if any, is much smaller than for BRCA1, BRCA2 or PALB2 mutations. If this applies to all truncating variants in FANCC it would suggest there are differences between FA genes in their roles on breast cancer risk and demonstrates the merit of large consortia for clarifying risk associations of rare variants.
Background: Preservation of kidney function in newly diagnosed (ND) multiple myeloma (MM) helps to prevent excess toxicity. Patients (pts) from two prospective trials were analyzed, provided postinduction (PInd) restaging was performed. Pts received three cycles with bortezomib (btz), cyclophosphamide, and dexamethasone (dex; VCD) or btz, lenalidomide (len), and dex (VRd) or len, adriamycin, and dex (RAD). The minimum required estimated glomerular filtration rate (eGFR) was >30 mL/min. We analyzed the percent change of the renal function using the International Myeloma Working Group (IMWG) criteria and Kidney Disease: Improving Global Outcomes (KDIGO)-defined categories. Results: Seven hundred and seventy-two patients were eligible. Three hundred and fifty-six received VCD, 214 VRd, and 202 RAD. VCD patients had the best baseline eGFR. The proportion of pts with eGFR <45 mL/min decreased from 7.3% at baseline to 1.9% PInd (p < 0.0001). Thirty-seven point one percent of VCD versus 49% of VRd patients had a decrease of GFR (p = 0.0872). IMWG-defined “renal complete response (CRrenal)” was achieved in 17/25 (68%) pts after VCD, 12/19 (63%) after RAD, and 14/27 (52%) after VRd (p = 0.4747). Conclusions: Analyzing a large and representative newly diagnosed myeloma (NDMM) group, we found no difference in CRrenal that occurred independently from the myeloma response across the three regimens. A trend towards deterioration of the renal function with VRd versus VCD may be explained by a better pretreatment “renal fitness” in the latter group.
Dieser Band der „Würzburger Studien zur Vor- und Frühgeschichtlichen Archäologie“ legt zum einen die Ergebnisse des DFG-Projektes „Konfliktvermeidung und Konfliktbeilegung in Gesellschaften ohne Zentralgewalt“ vor, das zwischen dem 1. April 2021 und dem 31. März 2024 am Lehrstuhl für Vor- und Frühgeschichtliche Archäologie des Instituts für Altertumswissenschaften der Julius-Maximilians-Universität Würzburg angesiedelt war und unter der Leitung des Herausgebers durchgeführt wurde. Sein einleitender Beitrag gliedert sich nach den drei Themen, die im Rahmen des Projektes bearbeitet wurden. Das erste zielte auf eine begriffliche Klärung des Phänomens der negativen Reziprozität, die nicht als Derivat oder Verfallserscheinung „eigentlicher“ Reziprozität zu verstehen ist, sondern gleichursprünglich mit der positiven in einer strukturellen Reziprozität gründet. Konkret geht es um die Frage, wie Beziehungen des Austauschs wechselseitiger schädigender Handlungen in Gang gesetzt werden, mittels welcher Mechanismen sie auf Dauer gestellt und wie sie gegebenenfalls beendet werden können. Ein wichtiger empirischer Faktor für den Umgang mit Dynamiken negativer Reziprozität ist die Erweiterung der dyadischen Konstellation zu einer triadischen durch Einbeziehung eines Dritten (oder von etwas Drittem). Die gängigen Konfliktmanagementtypologien beschreiben zumeist rollenförmig agierende, unparteiische, personale und singuläre Dritte, deshalb lag der Fokus im Kontext des Projektes auf Konfigurationen von Dritten, die von diesen Typologien invisibilisiert werden, das heißt auf parteiischen oder kollektiv verfassten Dritten sowie tatsächlich unsichtbaren, also imaginierten, fiktiven, abwesenden oder antizipierten Dritten. Und schließlich wurde untersucht, welche Bedeutungen der materiellen Kultur in Prozessen der Konfliktregelung zukommen, welche Funktionen konkrete Objekte übernehmen können bei der Definition und Einrichtung der Situation, der Symbolisierung von Transformationen und Fortschritten in Konfliktlösungsprozessen sowie der sinnfälligen und dauerhaften Symbolisierung der erzielten Ergebnisse.
No abstract available.
Purpose
Rescue missions during terrorist attacks are extremely challenging for all rescue forces (police as well as non-police forces) involved. To improve the quality and safety of the rescue missions during an active killing event, it is obligatory to adapt common rescue mission goals and strategies.
Methods
After the recent attacks in Europe, the Federal Office of Civil Protection and Disaster Assistance started an evaluation process on behalf of the Federal Ministry of the Interior and the Federal Ministry of Health. This was done to identify weaknesses, lessons learned and to formulate new adapted guidelines.
Results
The presented bullet point recommendations summarise the basic and most important results of the ongoing evaluation process for the Federal Republic of Germany. The safety of all the rescue forces and survival of the greatest possible number of casualties are the priority goals. Furthermore, the preservation and re-establishment of the socio-political integrity are the overarching goals of the management of active killing events. Strategic incident priorities are to stop the killing and to save as much lives as possible. The early identification and prioritised transportation of casualties with life-threatening non-controllable bleeding are major tasks and the shortest possible on-scene time is an important requirement with respect to safety issues.
Conclusion
With respect to hazard prevention tactics within Germany, we attributed the highest priority impact to the bullet points. The focus of the process has now shifted to intense work about possible solutions for the identified deficits and implementation strategies of such solutions during mass killing incidents.
Translating basic biological knowledge into applications remains a key issue for effectively tackling neurodegenerative, neuroinflammatory, or neuroendocrine disorders. Efficient delivery of therapeutics across the neuroprotective blood‐brain barrier (BBB) still poses a demanding challenge for drug development targeting central nervous system diseases. Validated in vitro models of the BBB could facilitate effective testing of drug candidates targeting the brain early in the drug discovery process during lead generation. We here review the potential of mono‐ or (isogenic) co‐culture BBB models based on brain capillary endothelial cells (BCECs) derived from human‐induced pluripotent stem cells (hiPSCs), and compare them to several available BBB in vitro models from primary human or non‐human cells and to rodent in vivo models, as well as to classical and widely used barrier models [Caco‐2, parallel artificial membrane permeability assay (PAMPA)]. In particular, we are discussing the features and predictivity of these models and how hiPSC‐derived BBB models could impact future discovery and development of novel CNS‐targeting therapeutics.
The MYC oncoprotein binds to promoter-proximal regions of virtually all transcribed genes and enhances RNA polymerase II (Pol II) function, but its precise mode of action is poorly understood. Using mass spectrometry of both MYC and Pol II complexes, we show here that MYC controls the assembly of Pol II with a small set of transcription elongation factors that includes SPT5, a subunit of the elongation factor DSIF. MYC directly binds SPT5, recruits SPT5 to promoters, and enables the CDK7-dependent transfer of SPT5 onto Pol II. Consistent with known functions of SPT5, MYC is required for fast and processive transcription elongation. Intriguingly, the high levels of MYC that are expressed in tumors sequester SPT5 into non-functional complexes, thereby decreasing the expression of growth-suppressive genes. Altogether, these results argue that MYC controls the productive assembly of processive Pol II elongation complexes and provide insight into how oncogenic levels of MYC permit uncontrolled cellular growth.